$NEPH
NEPHROS INC

2024 Q2 Form 10-Q Financial Statement

#000149315224018483 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $3.252M $3.522M $3.697M
YoY Change -8.27% -4.73% 69.04%
Cost Of Revenue $1.340M $1.335M $1.586M
YoY Change -8.59% -15.83% 36.49%
Gross Profit $1.912M $2.187M $2.111M
YoY Change -8.03% 3.6% 105.95%
Gross Profit Margin 58.79% 62.1% 57.1%
Selling, General & Admin $1.941M $2.142M $2.124M
YoY Change -13.31% 0.85% -9.11%
% of Gross Profit 101.52% 97.94% 100.62%
Research & Development $254.0K $212.0K $239.0K
YoY Change 14.93% -11.3% -58.65%
% of Gross Profit 13.28% 9.69% 11.32%
Depreciation & Amortization $35.00K $11.00K $9.000K
YoY Change -35.19% 22.22% -90.22%
% of Gross Profit 1.83% 0.5% 0.43%
Operating Expenses $2.229M $2.387M $2.417M
YoY Change -11.34% -1.24% -18.84%
Operating Profit -$317.0K -$200.0K -$306.0K
YoY Change -27.13% -34.64% -84.33%
Interest Expense $21.00K $1.000K $1.000K
YoY Change 0.0% -120.0%
% of Operating Profit
Other Income/Expense, Net $28.00K $31.00K
YoY Change 1300.0%
Pretax Income -$289.0K -$169.0K -$306.0K
YoY Change -33.26% -44.77% -84.44%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$289.0K -$169.0K -$306.0K
YoY Change -33.26% -44.77% -84.44%
Net Earnings / Revenue -8.89% -4.8% -8.28%
Basic Earnings Per Share -$0.03 -$0.02 -$0.03
Diluted Earnings Per Share -$0.03 -$0.02 -$0.03
COMMON SHARES
Basic Shares Outstanding 10.54M shares 10.54M shares 10.46M shares
Diluted Shares Outstanding 10.51M shares 10.50M shares 10.30M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.080M $3.633M $3.836M
YoY Change -24.14% -5.29% -29.24%
Cash & Equivalents $3.080M $3.633M $3.836M
Short-Term Investments
Other Short-Term Assets $165.0K $200.0K $177.0K
YoY Change 8.55% 12.99% -32.95%
Inventory $2.803M $2.779M $2.348M
Prepaid Expenses
Receivables $1.878M $1.518M $1.963M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.926M $8.130M $8.324M
YoY Change 0.15% -2.33% -28.59%
LONG-TERM ASSETS
Property, Plant & Equipment $186.0K $142.0K $107.0K
YoY Change 89.8% 32.71% -89.59%
Goodwill $800.0K $800.0K $800.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $70.00K $75.00K $60.00K
YoY Change 29.63% 25.0% -28.57%
Total Long-Term Assets $3.174M $3.286M $2.603M
YoY Change 28.4% 26.24% -32.76%
TOTAL ASSETS
Total Short-Term Assets $7.926M $8.130M $8.324M
Total Long-Term Assets $3.174M $3.286M $2.603M
Total Assets $11.10M $11.42M $10.93M
YoY Change 6.87% 4.48% -29.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.159M $1.114M $719.0K
YoY Change 283.77% 54.94% -19.84%
Accrued Expenses $435.0K $413.0K $383.0K
YoY Change -23.95% 7.83% -34.64%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.000K $2.000K $7.000K
YoY Change -87.5% -71.43% -97.36%
Total Short-Term Liabilities $1.952M $1.929M $1.415M
YoY Change 63.07% 36.33% -19.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.000K
YoY Change -100.0% -94.44%
Other Long-Term Liabilities $1.222M $1.307M $616.0K
YoY Change 128.84% 112.18% 80.12%
Total Long-Term Liabilities $1.222M $1.307M $618.0K
YoY Change 128.84% 111.49% 63.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.952M $1.929M $1.415M
Total Long-Term Liabilities $1.222M $1.307M $618.0K
Total Liabilities $3.174M $3.236M $2.033M
YoY Change 83.36% 59.17% -62.13%
SHAREHOLDERS EQUITY
Retained Earnings -$144.9M -$144.6M -$143.1M
YoY Change 0.91% 1.05%
Common Stock $11.00K $10.00K $10.00K
YoY Change 10.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.926M $8.180M $8.894M
YoY Change
Total Liabilities & Shareholders Equity $11.10M $11.42M $10.93M
YoY Change 6.87% 4.48% -29.63%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$289.0K -$169.0K -$306.0K
YoY Change -33.26% -44.77% -84.44%
Depreciation, Depletion And Amortization $35.00K $11.00K $9.000K
YoY Change -35.19% 22.22% -90.22%
Cash From Operating Activities -$501.0K -$672.0K $276.0K
YoY Change -321.68% -343.48% -115.36%
INVESTING ACTIVITIES
Capital Expenditures $55.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.000K $0.00
YoY Change
Cash From Investing Activities -$50.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000K -$2.000K -$74.00K
YoY Change 0.0% -97.3% -126.33%
NET CHANGE
Cash From Operating Activities -501.0K -$672.0K $276.0K
Cash From Investing Activities -50.00K 0.000
Cash From Financing Activities -2.000K -$2.000K -$74.00K
Net Change In Cash -553.0K -$674.0K $202.0K
YoY Change -346.88% -433.66% -113.03%
FREE CASH FLOW
Cash From Operating Activities -$501.0K -$672.0K $276.0K
Capital Expenditures $55.00K
Free Cash Flow -$556.0K $276.0K
YoY Change -346.02% -115.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001196298
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CY2023Q1 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
usd
CY2024Q1 NEPH Principal Payments On Equipment Financing
PrincipalPaymentsOnEquipmentFinancing
usd
CY2024Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
usd
CY2024Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
usd
CY2024Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-32288
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NEPHROS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3971809
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
380 Lackawanna Place
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South Orange
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07079
CY2024Q1 dei City Area Code
CityAreaCode
(201)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
343-5202
CY2024Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
NEPH
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10544139 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4307000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1496000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2470000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
132000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
8405000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
152000 usd
CY2023Q4 NEPH Operating And Finance Lease Right Of Use Assets
OperatingAndFinanceLeaseRightOfUseAssets
1807000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
381000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
759000 usd
CY2023Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
271000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
86000 usd
CY2023Q4 us-gaap Assets
Assets
11861000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
873000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
794000 usd
CY2023Q4 NEPH Operating And Finance Lease Liabilities Current
OperatingAndFinanceLeaseLiabilitiesCurrent
446000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2113000 usd
CY2023Q4 NEPH Operating And Finance Lease Liabilities Non Current
OperatingAndFinanceLeaseLiabilitiesNonCurrent
1390000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3503000 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10544139 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10544139 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10543675 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10543675 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
152754000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-144406000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8358000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11861000 usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
2187000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
2111000 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2142000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2124000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
212000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
239000 usd
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
33000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
54000 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
2387000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2417000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-200000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-306000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
1000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
1000 usd
CY2024Q1 us-gaap Interest Income Other
InterestIncomeOther
25000 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
12000 usd
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-169000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-306000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10501771 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10501771 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10297429 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10297429 shares
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-169000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-306000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8358000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-169000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-9000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8180000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8881000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
8894000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-169000 usd
CY2024Q1 us-gaap Depreciation
Depreciation
11000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
10000 usd
CY2024Q1 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
23000 usd
CY2023Q1 us-gaap Amortization Of Deferred Charges
AmortizationOfDeferredCharges
44000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
-9000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
319000 usd
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
73000 usd
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
91000 usd
CY2024Q1 NEPH Change In Right Of Use Asset
ChangeInRightOfUseAsset
125000 usd
CY2023Q1 NEPH Change In Right Of Use Asset
ChangeInRightOfUseAsset
87000 usd
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
3000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
22000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
677000 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
382000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-714000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
69000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10000 usd
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-11000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
244000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-21000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-380000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
98000 usd
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-125000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-87000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-672000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
276000 usd
CY2024Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000 usd
CY2023Q1 NEPH Principal Payments On Equipment Financing
PrincipalPaymentsOnEquipmentFinancing
1000 usd
CY2023Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
71000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-74000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-674000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
202000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4307000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3634000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3633000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3836000 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1000 usd
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_806_eus-gaap--NatureOfOperations_zKCDKwU0Alzj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_822_zr1CF8iz2oEd">Organization and Nature of Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. The Company was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced end stage renal disease (“ESRD”) therapy technology and products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning in 2009, Nephros introduced high performance liquid purification filters to meet the demand for water purification in certain medical markets. The Company’s filters, generally classified as ultrafilters, are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate. The Company also develops and sells water filtration products for commercial applications, focusing on the hospitality and food service markets. The water filtration business is a reportable segment, referred to as the Water Filtration segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2018, the Company formed a subsidiary, Specialty Renal Products, Inc. (“SRP”), to drive the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. After SRP’s formation, the Company assigned to SRP all of the Company’s rights to three patents relating to the Company’s hemodiafiltration technology, which were carried at zero book value. On March 9, 2023, the SRP Stockholders approved a plan of dissolution to wind down SRP’s operations, liquidate SRP’s remaining assets and dissolve SRP, and SRP filed a certificate of dissolution with the State of Delaware on April 13, 2023. As a result of the SRP Stockholders’ approval of the plan of dissolution and provisions therein and after satisfying all of SRP’s liabilities, there are no assets available for distribution to the holders of any of SRP’s capital stock, including its Series A Preferred Stock. As such, the value recorded to non-controlling interest was written to zero and the impact reclassified to the Company’s additional paid-in capital as the Company retained control of SRP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s primary U.S. facility is located at 380 Lackawanna Place, South Orange, New Jersey 07079. This location along with our Whippany, NJ facility, houses the Company’s corporate headquarters, research, manufacturing, and distribution facilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zZ8IkqDty9A9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zRwwk7u7VtOf">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amount of revenues and expenses, during the reporting period. Actual results could differ materially from those estimates. Included in these estimates are assumptions about the collection of accounts receivable, value of inventories, useful life of fixed assets and intangible assets, the assessment of expected cash flows used in evaluating goodwill and other long-lived assets, the assessment of the ability to continue as a going concern and assumptions used in determining stock compensation such as expected volatility and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-144600000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
800000 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zV2ECbLYZSub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zOre1KpYGbAl">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company deposits its cash in financial institutions. At times, such deposits may be in excess of insured limits. To date, the Company has not experienced any impairment losses on its cash. The Company also limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
11000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
11000 usd
CY2024Q1 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
1000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
1000 usd
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2390000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2144000 usd
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
389000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
326000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
2779000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
2470000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
540000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-167000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
373000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
540000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-159000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
381000 usd
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
24000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
32000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
32000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
32000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
32000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
32000 usd
CY2024Q1 us-gaap Goodwill
Goodwill
800000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
800000 usd
CY2024Q1 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
2300000 usd
CY2023Q4 us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
EURIBOR 360-day rate plus 500 basis points calculated on the principal amount of any outstanding invoices that are overdue by more than 15 days beyond the original payment terms
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
125000 usd
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
92000 usd
CY2024Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000 usd
CY2023 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
2000 usd
CY2024Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 usd
CY2023 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1000 usd
CY2024Q1 NEPH Finance Lease Cost
FinanceLeaseCost
3000 usd
CY2023 NEPH Finance Lease Cost
FinanceLeaseCost
3000 usd
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
11000 usd
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
4000 usd
CY2024Q1 us-gaap Lease Cost
LeaseCost
139000 usd
CY2023 us-gaap Lease Cost
LeaseCost
99000 usd
CY2024Q1 NEPH Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
158000 usd
CY2023 NEPH Operating Cash Flows From Operating Leases
OperatingCashFlowsFromOperatingLeases
87000 usd
CY2024Q1 NEPH Financing Cash Flows From Finance Leases
FinancingCashFlowsFromFinanceLeases
2000 usd
CY2023 NEPH Financing Cash Flows From Finance Leases
FinancingCashFlowsFromFinanceLeases
2000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1678000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1803000 usd
CY2024Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2000 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
4000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
400000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
442000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1307000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1390000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1707000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1832000 usd
CY2024Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2000 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4000 usd
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
2000 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
4000 usd
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2024Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2024Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.080 pure
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
404000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
2000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
435000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
450000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
450000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
251000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1990000 usd
CY2024Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
2000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
283000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1707000 usd
CY2024Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
2000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
579000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D

Files In Submission

Name View Source Status
neph-20240331_cal.xml Edgar Link unprocessable
0001493152-24-018483-index-headers.html Edgar Link pending
0001493152-24-018483-index.html Edgar Link pending
0001493152-24-018483.txt Edgar Link pending
0001493152-24-018483-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
neph-20240331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
neph-20240331_def.xml Edgar Link unprocessable
neph-20240331_lab.xml Edgar Link unprocessable
neph-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
Show.js Edgar Link pending